PD16-08 EFFECT OF CABAZITAXEL VS ABIRATERONE OR ENZALUTAMIDE ON PATIENT-REPORTED OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: A PRE-PLANNED EQ-5D-5L ANALYSIS OF THE CARD STUDY

Authors :: Jean-Christophe Eymard
Cora N. Sternberg
Ásgerður Sverrisdóttir
Carole Helissey
Roberto Iacovelli
Ronald de Wit
Ayse Ozatilgan
Christine Theodore
Daniel Castellano
Christine Geffriaud-Ricouard
Bertrand Tombal
Bohuslav Melichar
Johann S. de Bono
Joan Carles
Gero Kramer
Michail Liontos
Christian Wülfing
Susan Feyerabend
Karim Fizazi
Source :: Journal of Urology. 203
Publication Year :: 2020
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2020.
Abstract: INTRODUCTION AND OBJECTIVE:The results of the CARD (NCT02485691) study demonstrated superiority of cabazitaxel (CBZ) vs abiraterone or enzalutamide in patients with metastatic castration-resistant ...

Subjects :: Oncology
medicine.medical_specialty
business.industry
Urology
Castration resistant
medicine.disease
chemistry.chemical_compound
Prostate cancer
Abiraterone
chemistry
EQ-5D
Cabazitaxel
Internal medicine
Enzalutamide
Medicine
In patient
business
medicine.drug

Full Text Access

Tools